Biliary Tumors

1. A Phase II Trial of Bevacizumab and Erlotinib in Patients with Advanced Biliary Tumors (NCI study in collaboration with Mayo Phase II Consortium).

Breast Cancer

1. A Phase I/II study of weekly Paclitaxel and ORZEL (UFT + Leucovorin) in patients with metastatic breast cancer.

Colorectal Cancer

1. Phase II study of biweekly Irinotecan (CPT-11), 5-Fluorouracil (5FU) and Folinic Acid (FA) in unresectable liver metastases from colorectal cancer.
2. Phase II study of 5-Fluorouracil, Folinic Acid, Gemcitabine and Cisplatin as the second line treatment in patients with metastatic or recurrent colorectal carcinoma.
3. A Phase II Study of 5Azacitidine and SNDX-275 in Patients with Metastic Colorectal Cancer (NCI study in collaboration with Mayo Phase II Consortium).

Gastric Cancer

1. Phase II trial of pre-operative Docetaxel, Cisplatin and continuous infusion 5FU in patients with locally advanced gastric adenocarcinoma.
2. Phase II clinical trial of a novel tubulin-interacting macrolide in advanced
   local or metastatic gastric cancer (collaboration with a multi-national pharmaceutical company).
3. A Phase II study of Irofulven as first line therapy in recurrent or metastatic gastric cancer (NCI study).

Hepatocellular Carcinoma

1. Survey of angiogenic factors in HCC
2. A Phase II trial of Thalidomide in unresectable HCC.
3. Phase II trial of PS-341 in patients with hepatocellular carcinoma (NCI study in collaboration with Mayo Phase II Consortium).
4. A Phase I/II study of PXD101 in patients with unresectable hepatocellular carcinoma with pharmacokinetic and pharmacodynamic evaluation (NCI study).

Hepatoma

1. Hepatoma — Validation of CUPI.

Multiple Myeloma

1. A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma (NCI study in collaboration with Mayo Phase II Consortium).

Nasopharyngeal Carcinoma

1. Phase II study of Cetuximab with Carboplatin in patients with metastatic NPC.
2. Phase II study of Ifosphamide and Doxorubicin in Patients with Refractory Nasopharyngeal Carcinoma.
3. A Phase II Trial of VELCADE in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma.

Non Small Cell Lung Cancer

1. Phase II study of Taxotere & Carboplatin combination in resectable metastatic and locally advanced NSCLC.
2. Phase I study of Gemcitabine in conjunction with Vinorelbine and Radiotherapy in the Management of Stage IIIB or medically non-resectable non-small cell lung cancer (NSCLC).
3. Phase I/II trial of infusional Gemcitabine in combination with Carboplatin in chemo-naive advanced NSCLC.
4. A Phase II study of Triapine And Gemcitabine as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Patients Who Had Prior Gemcitabine with Evaluation of the Effect of Triapine on Gemcitabine Pharmacokinetics and Cellular Uptake in Peripheral Mononuclear Cells (NCI study).

Pancreas Cancer

1. A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer (NCI study in collaboration with Mayo Phase II Consortium).

Prostate Cancer

1. A Phase II study of Fenretinide in Patients with Hormone Refractory Prostate Cancer (NCI study).

Soft Tissue Sarcomas

1. A Phase II Study of Suberoylanilide hydroxamic acid and Bortezomib in Advanced Soft Tissue Sarcomas (NCI study in collaboration with Mayo Phase II Consortium).

Urothelial Cancer

1. A Phase II Study and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients with Metastatic Urothelial Cancer (NCI study in collaboration with Mayo Phase II Consortium).

Others

1. Study of genetic predisposition to chemotherapy-related toxicity.